Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 10/09/2023 at 12:45, 1 year 1 month ago

Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
PRESS RELEASE

published on 10/04/2023 at 07:00, 1 year 1 month ago

Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
PRESS RELEASE

published on 10/02/2023 at 07:00, 1 year 1 month ago

Newron appoints Margarita Chavez as board advisor
PRESS RELEASE

published on 08/04/2023 at 07:00, 1 year 3 months ago

Newron announces H1 2023 results and provides R&D update
PRESS RELEASE

published on 05/15/2023 at 07:00, 1 year 6 months ago

Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
PRESS RELEASE

published on 05/03/2023 at 07:00, 1 year 6 months ago

Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
PRESS RELEASE

published on 05/02/2023 at 07:00, 1 year 6 months ago

Newron announces Senior Management Team changes
PRESS RELEASE

published on 04/18/2023 at 12:15, 1 year 7 months ago

Newron announces AGM 2023 results
PRESS RELEASE

published on 03/28/2023 at 12:30, 1 year 7 months ago

Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
PRESS RELEASE

published on 03/20/2023 at 07:00, 1 year 8 months ago

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Published on 11/21/2024 at 16:01, 29 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 30 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 30 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 30 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:30, 1 hour ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 30 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 48 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 32 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 22 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 10 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News